Citigroup’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-110,134
| Closed | -$4.15M | – | 6615 |
|
|
2021
Q1 | $4.15M | Buy |
110,134
+102,686
| +1,379% | +$2.56M | ﹤0.01% | 1914 |
|
|
2020
Q4 | $127K | Buy |
7,448
+6,093
| +450% | +$76.3K | ﹤0.01% | 5347 |
|
|
2020
Q3 | $6K | Sell |
1,355
-2,510
| -65% | -$12.7K | ﹤0.01% | 6960 |
|
|
2020
Q2 | $24K | Sell |
3,865
-6,428
| -62% | -$26.5K | ﹤0.01% | 6497 |
|
|
2020
Q1 | $23K | Buy |
10,293
+3,445
| +50% | +$14.6K | ﹤0.01% | 6622 |
|
|
2019
Q4 | $31K | Sell |
6,848
-28,902
| -81% | -$114K | ﹤0.01% | 6700 |
|
|
2019
Q3 | $139K | Buy |
35,750
+17,336
| +94% | +$95.1K | ﹤0.01% | 5443 |
|
|
2019
Q2 | $111K | Buy |
18,414
+4,963
| +37% | +$47.5K | ﹤0.01% | 5772 |
|
|
2019
Q1 | $180K | Sell |
13,451
-126,424
| -90% | -$1.44M | ﹤0.01% | 5211 |
|
|
2018
Q4 | $1.3M | Buy |
139,875
+86,347
| +161% | +$1.03M | ﹤0.01% | 3126 |
|
|
2018
Q3 | $745K | Buy |
53,528
+33,741
| +171% | +$502K | ﹤0.01% | 3815 |
|
|
2018
Q2 | $313K | Sell |
19,787
-1,266
| -6% | -$22.1K | ﹤0.01% | 4591 |
|
|
2018
Q1 | $362K | Sell |
21,053
-49,614
| -70% | -$968K | ﹤0.01% | 4330 |
|
|
2017
Q4 | $1.55M | Buy |
70,667
+45,035
| +176% | +$1.45M | ﹤0.01% | 2912 |
|
|
2017
Q3 | $1.05M | Sell |
25,632
-20,599
| -45% | -$647K | ﹤0.01% | 3326 |
|
|
2017
Q2 | $1.39M | Buy |
46,231
+13,959
| +43% | +$436K | ﹤0.01% | 2963 |
|
|
2017
Q1 | $1.17M | Sell |
32,272
-70,396
| -69% | -$3.1M | ﹤0.01% | 3049 |
|
|
2016
Q4 | $5.14M | Buy |
102,668
+86,633
| +540% | +$4.55M | ﹤0.01% | 1808 |
|
|
2016
Q3 | $842K | Buy |
16,035
+6,283
| +64% | +$300K | ﹤0.01% | 3413 |
|
|
2016
Q2 | $403K | Sell |
9,752
-14,134
| -59% | -$615K | ﹤0.01% | 3877 |
|
|
2016
Q1 | $970K | Buy |
23,886
+12,698
| +113% | +$436K | ﹤0.01% | 3379 |
|
|
2015
Q4 | $465K | Sell |
11,188
-27,918
| -71% | -$936K | ﹤0.01% | 3935 |
|
|
2015
Q3 | $602K | Buy |
39,106
+25,783
| +194% | +$554K | ﹤0.01% | 3565 |
|
|
2015
Q2 | $331K | Sell |
13,323
-76,736
| -85% | -$1.71M | ﹤0.01% | 4058 |
|
|
2015
Q1 | $2.06M | Buy |
90,059
+75,767
| +530% | +$1.91M | ﹤0.01% | 2454 |
|
|
2014
Q4 | $386K | Buy |
14,292
+6,867
| +92% | +$118K | ﹤0.01% | 4122 |
|
|
2014
Q3 | $87K | Sell |
7,425
-2,369
| -24% | -$29.9K | ﹤0.01% | 4884 |
|
|
2014
Q2 | $152K | Sell |
9,794
-875
| -8% | -$12.5K | ﹤0.01% | 4355 |
|
|
2014
Q1 | $210K | Buy |
10,669
+7,950
| +292% | +$135K | ﹤0.01% | 4282 |
|
|
2013
Q4 | $46K | Buy |
+2,719
| New | +$33.8K | ﹤0.01% | 5766 |
|
Citigroup's FPRX Position: Q2 2021 in Review
Citigroup sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 110,134 shares — an estimated $4.15M sold.
Citigroup first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $5.14M in Q4 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Citigroup reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Citigroup sold 110,134 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $4.15M.
- Citigroup first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
- Citigroup's Five Prime Therapeutics, Inc. position peaked at $5.14M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.